Allspring Global Investments Holdings LLC grew its stake in Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) by 9,188.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 46,535 shares of the company’s stock after buying an additional 46,034 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Adicet Bio were worth $661,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Ziegler Capital Management LLC purchased a new position in shares of Adicet Bio in the 3rd quarter valued at about $574,000. Legal & General Group Plc lifted its stake in Adicet Bio by 204.5% during the second quarter. Legal & General Group Plc now owns 6,358 shares of the company’s stock worth $93,000 after purchasing an additional 4,270 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Adicet Bio by 51.5% during the second quarter. Goldman Sachs Group Inc. now owns 345,547 shares of the company’s stock worth $5,045,000 after purchasing an additional 117,516 shares during the last quarter. DAFNA Capital Management LLC lifted its stake in Adicet Bio by 30.7% during the second quarter. DAFNA Capital Management LLC now owns 935,766 shares of the company’s stock worth $13,662,000 after purchasing an additional 219,894 shares during the last quarter. Finally, State Street Corp lifted its stake in Adicet Bio by 19.9% during the second quarter. State Street Corp now owns 475,856 shares of the company’s stock worth $6,947,000 after purchasing an additional 79,088 shares during the last quarter.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the company. StockNews.com assumed coverage on Adicet Bio in a research note on Wednesday, October 12th. They set a “sell” rating for the company. Wedbush boosted their price objective on Adicet Bio to $30.00 in a research note on Wednesday, November 16th. Finally, HC Wainwright boosted their price objective on Adicet Bio from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 12th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Adicet Bio has a consensus rating of “Moderate Buy” and an average target price of $27.71.
Adicet Bio Trading Up 6.5 %
NASDAQ:ACET opened at $8.84 on Monday. The stock’s 50 day simple moving average is $12.52 and its 200-day simple moving average is $14.90. Adicet Bio, Inc. has a 12-month low of $7.42 and a 12-month high of $21.87. The firm has a market cap of $378.80 million, a P/E ratio of -6.05 and a beta of 2.29.
Adicet Bio (NASDAQ:ACET – Get Rating) last issued its quarterly earnings data on Tuesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.03. Research analysts forecast that Adicet Bio, Inc. will post -1.54 EPS for the current fiscal year.
Adicet Bio Profile
Adicet Bio, Inc is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
- Get a free copy of the StockNews.com research report on Adicet Bio (ACET)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.